Corticosteroids and immunomodulators: Postoperative infectious complication risk in inflammatory bowel disease patients

Gastroenterology

Volumn 125, Issue 2, 2003, Pages 320-327

  Aberra, Faten N ^a   Lewis, James D ^a   Hass, David ^a   Rombeau, John L ^a   Osborne, Benjamin ^a   Lichtenstein, Gary R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; MERCAPTOPURINE; PREDNISONE;

ABDOMINAL ABSCESS; ADOLESCENT; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; COHORT ANALYSIS; COLON SURGERY; DRUG EFFECT; ENTERITIS; FEMALE; HOSPITAL DISCHARGE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERITONITIS; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME; URINARY TRACT INFECTION; WOUND DEHISCENCE; WOUND INFECTION;

EID: 0043033175     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(03)00883-7     Document Type: Article

References (27)

1. Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001;121:255-260.
2. Munkholm P, Langholz E, Davidsen M, Binder V. Intestinal cancer risk and mortality in patients with Crohn's disease. Gastroenterology 1993;105:1716-1723.
3. Langholz E, Munkholm P, Davidsen M, Binder V. Long-term prognosis of patients with ulcerative colitis. Ugeskr Laeger 1993;155:3767-3772.
4. Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:255-281.
5. Green JW, Wenzel RP. Postoperative wound infection: a controlled study of the increased duration of hospital stay and direct cost of hospitalization. Ann Surg 1977;185:264-268.
6. Drug facts and comparisons. Amsterdam, The Netherlands: Wolters Kluwer, 2000:1860-1861.
7. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-649.
8. Lamers CB, Griffioen G, van Hogezand RA, Veenendaal RA. Azathioprine: an update on clinical efficacy and safety in inflammatory bowel disease. Scand J Gastroenterol 1999;230(suppl): 111-115.
9. Stein RB, Hanauer SB. Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23:429-448.
10. Ehrlich HP, Hunt TK. Effects of cortisone and vitamin A on wound healing. Ann Surg 1968;167:324-328.
11. Furst MB, Stromberg BV, Blatchford GJ, Christensen MA, Thorson AG. Colonic anastomoses: bursting strength after corticosteroid treatment. Dis Colon Rectum 1994;37:12-15.
12. Hurst RD, Finco C, Rubin M, Michelassi F. Prospective analysis of perioperative morbidity in one hundred consecutive colectomies for ulcerative colitis. Surgery 1995;118:748-755.
13. Ziv Y, Church JM, Fazio VW, King TM, Lavery IC. Effect of systemic steroids on ileal pouch-anal anastomosis in patients with ulcerative colitis. Dis Colon Rectum 1996;39:504-508.
14. Allsop JR, Lee EC. Factors which influenced postoperative complications in patients with ulcerative colitis or Crohn's disease of the colon on corticosteroids. Gut 1978;19:729-734.
15. Mahadevan U, Loftus EV, Tremaine WJ, Pemberton JH, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis 2002;8:311-316.
16. Hyde G, Jewell M, Kettlewell M, Mortensen N. Cyclosporin for severe ulcerative colitis does not increase the rate of perioperative complications. Dis Colon Rectum 2001;44:1436-1440.
17. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-433.
18. Munkholm P, Langholz E, Davidsen M, Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994;35:360-362.
19. Silverstein MD, Loftus EV, Sandborn WJ, Tremaine WJ, Feagan BG, Nietert PJ, Harmsen WS, Zinsmeister Zinsmelster AR. Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort. Gastroenterology 1999;117:49-57.
20. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of Crohn's disease patients. Scand J Gastroenterol 1995;30:699-706.
21. Lewis J, Lichtenstein G, Brensinger C, Bilker W, Strom B. Characteristics of prior steroid use predicts duration of steroid therapy in inflammatory bowel disease (IBD) (abstr). Gastroenterology 2001;120:A-269.
22. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
23. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989;11:954-963.
24. Reding R, Michel LA, Donckier J, de Canniere L, Jamart J. Surgery in patients on long-term steroid therapy: a tentative model for risk assessment. Br J Surg 1990;77:1175-1178.
25. Dorp WV, Koote AM, Gemert GV, Van ES LA, Paul LC. Infections in renal transplant patients treated with cyclosporine or azathioprine. Scand J Infect Dis 1989;21:75-80.
26. Shaffer D, Hammer SM, Monaco AP. Infectious complications with the use of cyclosporine versus azathioprine after cadaveric kidney transplantation. Am J Surg 1987;153:381-386.
27. Strom BL, Carson JL, Halpern AC, Schinnar R, Snyder ES, Stolley PD, Shaw M, Tilson HH, Joseph M, Dai WS, et al. Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 1991;10:565-576.